Table 2. Clinical and pathological characteristics of gastric cancer patients according to the neutrophil-lymphocyte ratio subgroups.
| LL NLR n=105 (32.3%) | HL NLR n=59 (18.1%) | LH NLR n=57 (17.5%) | HH NLR n=104 (32%) | p value | ||
|---|---|---|---|---|---|---|
| Age, years | 0.008 | |||||
| (SD) | 58,9 (12,7) | 64,6 (11,9) | 62,3 (11,0) | 64 (12,4) | ||
| Sex | 0.107 | |||||
| Female | 47 (44.8) | 20 (33.9) | 27 (47.4) | 33 (31.7) | ||
| Male | 58 (55.2) | 39 (66.1) | 30 (52.6) | 71 (68.3) | ||
| BMI, kg/cm² | 24.6 (4.4) | 23.9 (5.5) | 25.1 (5.5) | 23.9 (4.5) | 0.389 | |
| Hemoglobin, g/dL | 12.6 (2.0) | 13.5 (16.4) | 12.8 (1.8) | 12 (2.2) | 0.626 | |
| Albumin, mg/dL | 4.1 (0.7) | 3.8 (0.7) | 4.1 (0.5) | 4.3 (3.1) | 0.467 | |
| CCI* | 0.454 | |||||
| 0 | 69 (65.7) | 38 (64.4) | 43 (75.4) | 66 (63.5) | ||
| ≥1 | 36 (34.3) | 21 (35.6) | 14 (24.6) | 38 (36.5) | ||
| ASA | 0.054 | |||||
| I/II | 87 (82.9) | 45 (76.3) | 54 (94.7) | 87 (83.7) | ||
| III/IV | 18 (17.1) | 14 (23.7) | 3 (5.3) | 17 (16.3) | ||
| Tumor site | 0.484 | |||||
| Non-upper | 98 (93.3) | 54 (91.5) | 49 (86) | 94 (90.4) | ||
| Upper | 7 (6.7) | 5 (8.5) | 8 (14) | 10 (9.6) | ||
| Type of resection | 0.701 | |||||
| Subtotal | 28 (26.7) | 16 (27.1) | 11 (19.3) | 28 (26.9) | ||
| Total | 77 (73.3) | 43 (72.9) | 46 (80.7) | 76 (73.1) | ||
| Histological grade | 0.676 | |||||
| G1/G2 | 50 (47.6) | 27 (45.8) | 32 (56.1) | 50 (48.1) | ||
| G3 | 55 (52.4) | 32 (54.2) | 25 (43.9) | 54 (51.9) | ||
| Lauren type | 0.434 | |||||
| Intestinal/ indeterminate | 50 (47.6) | 34 (57.6) | 34 (59.6) | 55 (52.9) | ||
| Diffuse/mixed | 55 (52.4) | 25 (42.4) | 23 (40.4) | 49 (47.1) | ||
| pT status | 0.086 | |||||
| pT1/T2 | 50 (47.6) | 19 (32.2) | 28 (49.1) | 37 (35.6) | ||
| pT3/T4 | 55 (52.4) | 40 (67.8) | 29 (50.9) | 67 (64.4) | ||
| pN status | 0.569 | |||||
| pN negative | 44 (41.9) | 21 (35.6) | 27 (47.4) | 47 (45.2) | ||
| pN positive | 61 (58.1) | 38 (64.4) | 30 (52.6) | 57 (54.8) | ||
| Stage** | 0.339 | |||||
| I/II | 55 (52.4) | 29 (49.2) | 37 (64.9) | 57 (54.8) | ||
| III | 50 (47.6) | 30 (50.8) | 20 (35.1) | 47 (45.2) | ||
| Postoperative complication | 0.014 | |||||
| No complication | 81 (77.1) | 39 (66.1) | 34 (59.6) | 80 (76.9) | ||
| Grade I-II | 15 (14.3) | 18 (30.5) | 13 (22.8) | 17 (16.3) | ||
| Grade III | 9 (8.6) | 2 (3.4) | 10 (17.5) | 7 (6.7) | ||
Results expressed as mean (standard deviation); n (%); mean (variation).
*
Value without neoplasia and age;
**
eighth edition of the American Joint Committee on Cancer (AJCC).
SD: standard deviation; BMI: body mass index; CCI: Charlson comorbidity index; ASA: American Society of Anesthesiologists; LL NLR: low pre and postoperative neutrophil-lymphocyte ratio; LH NLR: low pre and high postoperative neutrophil-lymphocyte ratio; HL NLR: high pre and low postoperative neutrophil-lymphocyte ratio; HH NLR: high pre and postoperative neutrophil-lymphocyte ratio.